Cargando…

Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity

Mostrar otras versiones (1)

Most antibodies isolated from COVID-19 patients are specific to SARS-CoV-2. COVA1–16 is a relatively rare antibody that also cross-neutralizes SARS-CoV. Here we determined a crystal structure of COVA1–16 Fab with the SARS-CoV-2 RBD, and a negative-stain EM reconstruction with the spike glycoprotein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hejun, Wu, Nicholas C., Yuan, Meng, Bangaru, Sandhya, Torres, Jonathan L., Caniels, Tom G., van Schooten, Jelle, Zhu, Xueyong, Lee, Chang-Chun D., Brouwer, Philip J.M., van Gils, Marit J., Sanders, Rogier W., Ward, Andrew B., Wilson, Ian A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418720/ https://www.ncbi.nlm.nih.gov/pubmed/32793906 http://dx.doi.org/10.1101/2020.08.02.233536

Ejemplares similares

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
por: Liu, Hejun, et al.
Publicado: (2020)

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
por: Wu, Nicholas C., et al.
Publicado: (2020)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
por: Radić, Laura, et al.
Publicado: (2023)

Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses
por: Yin, Victor, et al.
Publicado: (2021)

HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth
por: van Schooten, Jelle, et al.
Publicado: (2018)

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
por: Liu, Hejun, et al.
Publicado: (2021)

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
por: Liu, Hejun, et al.
Publicado: (2021)

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
por: Brouwer, Philip J. M., et al.
Publicado: (2020)

HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients
por: van den Kerkhof, Tom, et al.
Publicado: (2011)

Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
por: Brinkkemper, Mitch, et al.
Publicado: (2022)

A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
por: Brinkkemper, Mitch, et al.
Publicado: (2021)

A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike
por: van der Velden, Yme U., et al.
Publicado: (2022)

Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual
por: Guerra, Denise, et al.
Publicado: (2023)

Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
por: van Schooten, Jelle, et al.
Publicado: (2022)

Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein
por: van Schooten, Jelle, et al.
Publicado: (2022)

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds
por: van den Kerkhof, Tom L. G. M., et al.
Publicado: (2016)

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users
por: EULER, Zelda, et al.
Publicado: (2019)

Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies
por: Perrett, Hailee R., et al.
Publicado: (2023)

A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA
por: Bangaru, Sandhya, et al.
Publicado: (2018)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity
por: van den Kerkhof, Tom L G M, et al.
Publicado: (2013)

Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate
por: Sliepen, Kwinten, et al.
Publicado: (2022)

Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies
por: Yuan, Meng, et al.
Publicado: (2019)

The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization
por: Schorcht, Anna, et al.
Publicado: (2022)

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
por: Maisonnasse, Pauline, et al.
Publicado: (2021)

Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
por: van Rijswijck, Danique M. H., et al.
Publicado: (2022)

Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection
por: Brouwer, Philip J.M., et al.
Publicado: (2022)

Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles
por: Brouwer, Philip J. M., et al.
Publicado: (2021)

Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice
por: van der Velden, Yme U., et al.
Publicado: (2020)

Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention
por: Wagh, Kshitij, et al.
Publicado: (2021)

Signatures of V(H)1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteins
por: Capella-Pujol, Joan, et al.
Publicado: (2023)

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
por: Yuan, Meng, et al.
Publicado: (2021)

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
por: Yuan, Meng, et al.
Publicado: (2021)

Model-based inference of neutralizing antibody avidities against influenza virus
por: Linnik, Janina, et al.
Publicado: (2022)

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
por: Wu, Nicholas C., et al.
Publicado: (2020)

Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers
por: Schorcht, Anna, et al.
Publicado: (2020)

Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity
por: Rujas, Edurne, et al.
Publicado: (2022)

Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
por: Du, Wenjuan, et al.
Publicado: (2023)

Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner
por: Amanat, Fatima, et al.
Publicado: (2021)

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
por: Wu, Nicholas C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k7j46emk9s98j23kddituslj8t